Burden and Predictors of Non-Alcoholic Fatty Liver Disease in a Retrospective Cohort of Patients With Crohn's Disease.
Crohn’s disease
Non-alcoholic fatty liver disease
Non-alcoholic steatohepatitis
Steatosis
Vitamin B12 deficiency
Journal
Gastroenterology research
ISSN: 1918-2805
Titre abrégé: Gastroenterology Res
Pays: Canada
ID NLM: 101519422
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
13
02
2022
accepted:
16
03
2022
entrez:
16
5
2022
pubmed:
17
5
2022
medline:
17
5
2022
Statut:
ppublish
Résumé
Non-alcoholic fatty liver disease (NAFLD) is an emerging extraintestinal manifestation (EIM) of Crohn's disease (CD). We aimed to investigate the prevalence and comorbid predictors of NAFLD in patients with CD. We conducted a nationwide retrospective cohort study to determine the prevalence, characteristics, comorbidities, and hospitalization outcomes associated with NAFLD in patients with CD. Comparison between groups was performed by Mann-Whitney test for continuous variables and Chi-square test for categorical variables. We performed a binary logistic regression analysis for predictors of NAFLD among patients with CD. We extracted 215,049 index hospital discharges with CD; 2.4% had NAFLD. CD patients, with NAFLD, had increased length of stay (4 days; interquartile range (IQR): 2 - 6 vs. 3; IQR: 2 - 6, P < 0.01), and increased median total charges ($32,305.5; IQR: $18,600 - $61,599 vs. $30,782; IQR: $16,847 - $58,667, P < 0.01), compared to CD patients without NAFLD. Non-alcoholic steatohepatitis (NASH) was found to be independently associated with increased mortality (odds ratio (OR): 1.7; 95% confidence interval (CI): 1.1 - 2.6, P = 0.03) and a higher odd for all-cause 30-day non-elective readmission (OR: 1.6: 95% CI: 1.3 - 1.9, P < 0.001). Factors independently associated with NAFLD in patients with CD included portal hypertension (OR: 5.347; 95% CI: 4.604 - 6.211, P < 0.001), vitamin A deficiency (OR: 9.89; 95% CI: 4.49 - 21.76, P < 0.001) and vitamin B12 deficiency (OR: 1.56; 95% CI: 1.098 - 2.209, P = 0.013). NAFLD is associated with worse hospitalization outcomes in patients with CD. Study findings suggest the need for early identification and effective management of NAFLD predictors to reduce complications.
Sections du résumé
Background
UNASSIGNED
Non-alcoholic fatty liver disease (NAFLD) is an emerging extraintestinal manifestation (EIM) of Crohn's disease (CD). We aimed to investigate the prevalence and comorbid predictors of NAFLD in patients with CD.
Methods
UNASSIGNED
We conducted a nationwide retrospective cohort study to determine the prevalence, characteristics, comorbidities, and hospitalization outcomes associated with NAFLD in patients with CD. Comparison between groups was performed by Mann-Whitney test for continuous variables and Chi-square test for categorical variables. We performed a binary logistic regression analysis for predictors of NAFLD among patients with CD.
Results
UNASSIGNED
We extracted 215,049 index hospital discharges with CD; 2.4% had NAFLD. CD patients, with NAFLD, had increased length of stay (4 days; interquartile range (IQR): 2 - 6 vs. 3; IQR: 2 - 6, P < 0.01), and increased median total charges ($32,305.5; IQR: $18,600 - $61,599 vs. $30,782; IQR: $16,847 - $58,667, P < 0.01), compared to CD patients without NAFLD. Non-alcoholic steatohepatitis (NASH) was found to be independently associated with increased mortality (odds ratio (OR): 1.7; 95% confidence interval (CI): 1.1 - 2.6, P = 0.03) and a higher odd for all-cause 30-day non-elective readmission (OR: 1.6: 95% CI: 1.3 - 1.9, P < 0.001). Factors independently associated with NAFLD in patients with CD included portal hypertension (OR: 5.347; 95% CI: 4.604 - 6.211, P < 0.001), vitamin A deficiency (OR: 9.89; 95% CI: 4.49 - 21.76, P < 0.001) and vitamin B12 deficiency (OR: 1.56; 95% CI: 1.098 - 2.209, P = 0.013).
Conclusions
UNASSIGNED
NAFLD is associated with worse hospitalization outcomes in patients with CD. Study findings suggest the need for early identification and effective management of NAFLD predictors to reduce complications.
Identifiants
pubmed: 35572477
doi: 10.14740/gr1509
pmc: PMC9076152
doi:
Types de publication
Journal Article
Langues
eng
Pagination
82-90Informations de copyright
Copyright 2022, Abomhya et al.
Déclaration de conflit d'intérêts
None to declare.
Références
Nutr Metab Cardiovasc Dis. 2007 Sep;17(7):517-24
pubmed: 16928437
Curr Pharm Des. 2013;19(15):2737-46
pubmed: 23092327
Am J Clin Nutr. 2015 Jul;102(1):130-7
pubmed: 25948673
Sci Rep. 2021 Mar 5;11(1):5283
pubmed: 33674694
Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11-20
pubmed: 28930295
Hepatology. 2018 Jan;67(1):328-357
pubmed: 28714183
Am J Bioeth. 2010 Sep;10(9):3-11
pubmed: 20818545
Gut. 2006 Mar;55(3):415-24
pubmed: 16174657
Gastroenterol Clin North Am. 2016 Dec;45(4):639-652
pubmed: 27837778
Semin Liver Dis. 2007 Feb;27(1):44-54
pubmed: 17295176
World J Gastroenterol. 2014 Oct 21;20(39):14205-18
pubmed: 25339807
Inflamm Bowel Dis. 2020 Jan 1;26(1):1-10
pubmed: 31112238
Nutr Metab Cardiovasc Dis. 2013 Aug;23(8):792-8
pubmed: 23415456
Hepatology. 2016 Jul;64(1):73-84
pubmed: 26707365
Clin Gastroenterol Hepatol. 2007 Dec;5(12):1430-8
pubmed: 18054751
Metabolism. 2016 Aug;65(8):1038-48
pubmed: 26823198
J Hepatol. 2009 Jul;51(1):176-86
pubmed: 19450891
Clin Gastroenterol Hepatol. 2007 Dec;5(12):1424-9
pubmed: 17904915
J Mol Med (Berl). 2014 Oct;92(10):1069-82
pubmed: 24861026
Gut. 2022 Apr;71(4):778-788
pubmed: 33685968
Mitochondrion. 2006 Feb;6(1):1-28
pubmed: 16406828
Hepatology. 2003 Apr;37(4):917-23
pubmed: 12668987
Clin Gastroenterol Hepatol. 2019 Dec;17(13):2816-2818
pubmed: 30876963
Clin Med Insights Gastroenterol. 2014 Jun 17;7:25-31
pubmed: 24966712
Am J Gastroenterol. 2016 Jan;111(1):15-23
pubmed: 26195179
Eur J Gastroenterol Hepatol. 2020 Aug;32(8):903-906
pubmed: 32044821
Hepatology. 2011 Jul;54(1):344-53
pubmed: 21520200
Pharmacoeconomics. 2015 Dec;33(12):1245-53
pubmed: 26233836
J Clin Invest. 2021 Feb 15;131(4):
pubmed: 33586673